StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)

Investment analysts at StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report released on Saturday. The brokerage set a “hold” rating on the stock.

TherapeuticsMD Price Performance

Shares of TherapeuticsMD stock opened at $1.11 on Friday. TherapeuticsMD has a 12 month low of $1.05 and a 12 month high of $2.75. The business has a fifty day simple moving average of $1.41 and a two-hundred day simple moving average of $1.64.

Hedge Funds Weigh In On TherapeuticsMD

An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP grew its holdings in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the period. Clearline Capital LP owned about 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.